Guerbet S.A. buy melinda
Start price
18.03.19
/
50%
€49.95
Target price
04.11.21
€65.00
Performance (%)
-39.94%
End price
01.07.21
€30.00
Summary
This prediction ended on 01.07.21 with a price of €30.00. The BUY prediction by melinda for Guerbet S.A. performed very badly with a performance of -39.94%. Dividends of €1.55 are taken into consideration when calculating the performance. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Guerbet S.A. | -10.131% | -10.131% | -54.272% | -41.010% |
| iShares Core DAX® | -2,20 % | 0,67 % | 0,55 % | 51,11 % |
| iShares Nasdaq 100 | -2,63 % | 2,99 % | 34,11 % | 91,99 % |
| iShares Nikkei 225® | -2,02 % | 3,14 % | 53,42 % | 65,85 % |
| iShares S&P 500 | -1,67 % | 2,40 % | 23,22 % | 66,64 % |
Comments by melinda for this prediction
In the thread Guerbet S.A. diskutieren
SecteurProduits pharmaceutiques Agenda 26/03 Publication de résultats
The CA for family product products - - products for imagerie by rayons X (46,6%);
- produits pour IRM (33,7%);
- autres (19,7%): products of contrast, not not to end échography and medical medicine, and products of chimie fine.
En 2017, le groupe dispose de 9 sites de production implémentés en France (4), aux etats unis (2), au Canada, en Irlande et au Brésil.
46,4% d'entre vous sont CA en Europe.
Nombre d'employés
: 2 762 personnes.